Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
数字之外：11位分析师讨论拜玛林制药股票
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Biomarin Pharmaceutical (NASDAQ:BMRN) in the last three months.
在过去三个月中，有11位分析师公布了对Biomarin Pharmaceutical（纳斯达克股票代码：BMRN）的评级，提供了从看涨到看跌的不同视角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $107.0, a high estimate of $120.00, and a low estimate of $86.00. This upward trend is evident, with the current average reflecting a 1.9% increase from the previous average price target of $105.00.
分析师为Biomarin Pharmaceutical设定了12个月的目标股价，显示平均目标股价为107.0美元，最高估计为120.00美元，低估值为86.00美元。这种上升趋势显而易见，当前的平均价格较之前的平均目标价105.00美元上涨了1.9％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析师评级：全面细分
The analysis...
对分...
登录免费看全文
登录/注册